Chronopharmacologic considerations when treating the patient with hypertension: a review
RJ Straka, SR Benson - The Journal of Clinical Pharmacology, 1996 - Wiley Online Library
Recognition of the existence of circadian variation in exacerbation of cardiovascular disease
may have relevance to clinical use of cardioactive agents. Physiologic rational for the …
may have relevance to clinical use of cardioactive agents. Physiologic rational for the …
Isradipine—another calcium-channel blocker for the treatment of hypertension and angina
LM Lopez, TM Santiago - Annals of Pharmacotherapy, 1992 - journals.sagepub.com
OBJECTIVE: To review the pharmacology, pharmacokinetic disposition, dose
recommendations, adverse effects, drug interactions, and efficacy of isradipine in patients …
recommendations, adverse effects, drug interactions, and efficacy of isradipine in patients …
Twenty-four hour profile of the anti-hypertensive action of isradipine in essential hypertension
CJS Low, SG Foy, H Chaudhary, IG Crozier… - Blood …, 1993 - Taylor & Francis
Isradipine, 2.5 mg twice daily and placebo were administered for 4 weeks to 11 untreated
essential hypertensives in a double-blind, random order, crossover study. At the end of each …
essential hypertensives in a double-blind, random order, crossover study. At the end of each …